These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24773330)

  • 1. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011.
    Gellad WF; Choi P; Mizah M; Good CB; Kesselheim AS
    Am J Manag Care; 2014 Mar; 20(3):e90-7. PubMed ID: 24773330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review.
    Long AS; Zhang AD; Meyer CE; Egilman AC; Ross JS; Wallach JD
    JAMA Netw Open; 2021 May; 4(5):e215731. PubMed ID: 33956134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-enantiomer drugs: elegant science, disappointing effects.
    Mansfield P; Henry D; Tonkin A
    Clin Pharmacokinet; 2004; 43(5):287-90. PubMed ID: 15080762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016.
    Dickson S
    J Manag Care Spec Pharm; 2019 Jul; 25(7):780-792. PubMed ID: 30799664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
    Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
    JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single enantiomer versus racemate: chiral distinction in the proton pump inhibitors omeprazole and esomeprazole.
    Marom H; Pogodin S; Agranat I
    Chirality; 2014 Apr; 26(4):214-27. PubMed ID: 24619931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of eszopiclone in the treatment of insomnia.
    Morin AK; Willett K
    Adv Ther; 2009 May; 26(5):500-18. PubMed ID: 19513631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A promise to a court doesn't avoid infringement.
    Harrison C
    Nat Rev Drug Discov; 2013 Nov; 12(11):820. PubMed ID: 24172324
    [No Abstract]   [Full Text] [Related]  

  • 14. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.